BioSpace News Archive

Structure Therapeutics Inc. today reported financial results for the fourth quarter and full year ended December 31, 2023, and highlighted recent corporate achievements.

Exagen Inc. today announced its participation in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum, which takes place virtually March 19-20, 2024.

Kane Biotech Inc. announces that at the Bioscience Association of Manitoba annual awards dinner held on March 7, 2024, Kane Biotech received the BAM Company of the Year award.

Mabwell announced that it will present the clinical study results on the efficacy and safety of the novel Nectin-4-targeting ADC 9MW2821 for patients with recurrent or metastatic cervical cancer as focused plenary oral presentation at the Society of Gynecologic Oncology (SGO) annual meeting on women’s cancer to be held in San Diego, USA, from March 16-18, 2024.

Agendia®, Inc., announced it will share new data from the ongoing prospective, observational FLEX Trial in two poster presentations at the 41st Annual Miami Breast Cancer Conference, taking place March 7 – 10th, 2024.

Biofrontera Inc. today announced that it will report financial results for the three and 12 months ended December 31, 2023 on Friday, March 15, 2024.

Kymera Therapeutics, Inc. (NASDAQ: KYMR) today announced that its preclinical data demonstrating the therapeutic potential of its potent and selective heterobifunctional degraders of STAT6 (KT-621) and TYK2 (KT-294) are being presented in the poster session at the American Academy of Dermatology’s Annual Meeting in San Diego, California.

Dallas-based board-certified dermatologist Seemal R. Desai, MD, FAAD, will begin his one-year term as president of the American Academy of Dermatology at the close of the AAD’s Annual Meeting.

3M announced that its Board of Directors has approved the planned spin-off of its Health Care business, which will be known as Solventum Corporation.

UCB, a global biopharmaceutical company, today announced 48-week post-hoc analyses of pooled Phase 3 data from the BE HEARD I and BE HEARD II studies examining the impact of BIMZELX on skin pain and draining tunnels in adults with moderate-to-severe hidradenitis suppurativa (HS).